SecBot SecBot
SECBOTREPLAY Home › Report › LAB

LAB · Standard BioTools (LAB) announced a transformative all-stock reverse…

STANDARD BIOTOOLS INC. · 425 filed Jun 8, 2026 at 08:35 ET

At the news

BULLISHIMPACT 7/10

425 filed Jun 8, 2026 at 08:35 ET

Standard BioTools (LAB) announced a transformative all-stock reverse merger with private biotech Treeline Biosciences. Treeline is valued at $2.5 billion, while LAB's net cash implies an equity value of ~$460 million. Former Treeline stockholders will own ~84% of the combined company on a fully diluted basis, with LAB holders retaining ~16%. LAB also plans to issue CVRs to its stockholders tied to monetization of its legacy businesses, capped at 76 million shares. The deal requires LAB stockholder approval and is expected to close in H2 2026.

  • All-stock reverse merger with Treeline Biosciences valued at $2.5B.
  • LAB implied equity value of ~$460M based on net cash at closing.
  • Former Treeline stockholders to own ~84% of combined company; LAB holders ~16%.
  • CVRs to be issued to LAB stockholders, capped at 76M shares, tied to legacy business monetization.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access